Cai H - Search Results

1

Efficacy and safety of adding bevacizumab biosimilar or original drug to platinum-based chemotherapy as first-line treatment in patients with advanced NSCLC: a systematic review and meta-analysis.

Yang L, Liu M, Cao X, Li N, Zheng B, Deng J, Cai H. Yang L, et al. Among authors: cai h. Ther Adv Med Oncol. 2022 Oct 20;14:17588359221130501. doi: 10.1177/17588359221130501. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36312816 Free PMC article.

2

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Li N, Zheng B, Cai HF, Yang J, Luo XF, Weng LZ, Zhan FM, Liu MB. Li N, et al. Clin Drug Investig. 2018 Jan;38(1):79-86. doi: 10.1007/s40261-017-0587-z. Clin Drug Investig. 2018. PMID: 29027641

3

Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China.

Cai H, Zhang L, Li N, Chen S, Zheng B, Yang J, Weng L, Liu MB. Cai H, et al. Clin Ther. 2019 Feb;41(2):280-290. doi: 10.1016/j.clinthera.2018.12.007. Epub 2019 Jan 11. Clin Ther. 2019. PMID: 30639208

4

Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.

Li N, Zheng B, Liu M, Zhou H, Zhao L, Cai H, Huang J. Li N, et al. Among authors: cai h. Menopause. 2019 Aug;26(8):906-914. doi: 10.1097/GME.0000000000001339. Menopause. 2019. PMID: 30994577

5

Pharmacokinetics and cardiotoxicity of doxorubicin and its secondary alcohol metabolite in rats.

Zeng X, Cai H, Yang J, Qiu H, Cheng Y, Liu M. Zeng X, et al. Among authors: cai h. Biomed Pharmacother. 2019 Aug;116:108964. doi: 10.1016/j.biopha.2019.108964. Epub 2019 May 15. Biomed Pharmacother. 2019. PMID: 31102935 Free article.

6

Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial.

Yang J, Weng L, Chen Z, Cai H, Lin X, Hu Z, Li N, Lin B, Zheng B, Zhuang Q, Du B, Zheng Z, Liu M. Yang J, et al. Among authors: cai h. JMIR Mhealth Uhealth. 2019 May 29;7(5):e12542. doi: 10.2196/12542. JMIR Mhealth Uhealth. 2019. PMID: 31144672 Free PMC article. Clinical Trial.

7

Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma.

Cai H, Zhang L, Li N, Zheng B, Liu M. Cai H, et al. Leuk Lymphoma. 2019 Dec;60(12):2951-2959. doi: 10.1080/10428194.2019.1620947. Epub 2019 Jun 4. Leuk Lymphoma. 2019. PMID: 31161831

8

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer.

Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Liu M, et al. Among authors: cai h. Cancer Manag Res. 2019 Oct 25;11:9195-9202. doi: 10.2147/CMAR.S223441. eCollection 2019. Cancer Manag Res. 2019. PMID: 31749634 Free PMC article.

9

Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States.

Liu M, Han S, Zheng B, Cai H, Yang J, Zhuang Q, Li N. Liu M, et al. Among authors: cai h. Cancer Manag Res. 2019 Nov 11;11:9483-9493. doi: 10.2147/CMAR.S226243. eCollection 2019. Cancer Manag Res. 2019. PMID: 31814756 Free PMC article.

10

Lenvatinib versus sorafenib for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Cai H, Zhang L, Li N, Zheng B, Liu M. Cai H, et al. J Comp Eff Res. 2020 Jun;9(8):553-562. doi: 10.2217/cer-2020-0041. Epub 2020 May 18. J Comp Eff Res. 2020. PMID: 32419473 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,984 results

Search Page

Filters